Press Room

AAPS 2022 PharmSci 360

Start
Sunday, October 16, 2022 - 09:00
End
Wednesday, October 19, 2022 - 17:00
Location: Boston, United States
Booth Number: 1043

Visit Hovione’s booth at AAPS PharmSci 360 next October 16-19 in Boston and meet our team of experts.

 

Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting.



Continuous tableting is suited for all type of drug products for oral delivery, including the production of precision medicines and breakthrough therapies. This technology assures robust supply of quality product through enhanced process control strategies while using the same equipment for development and commercial-scale production.

 

Hovione presentation with Luis Sobral at AAPS

HOVIONE PRESENTATION

On October 17th, don't miss our presentation: “Accelerate Manufacturing Processes Development with Computational Chemistry” with Luís Sobral, Fellow Scientist.

10:00 AM - 10:30 AM ET

 

Poster Sessions

Monday, October 17, 2022 | 2:30 PM – 3:30 PM ET

Poster: Use of PAT Tools in the Development, Monitor and Control of Continuous Manufacturing Processes

Presenting Author: Ricardo Sousa, MS - Senior Formulation Development Scientist, Hovione

Tuesday, October 18, 2022 | 9:30 AM – 10:30 AM ET

Poster: Enhancing the “Right First Time” Concept in Continuous Manufacturing–Development Strategy

Presenting Author: Ricardo Sousa, MS - Senior Formulation Development Scientist, Hovione

Tuesday, October 18, 2022 | 11:30 AM – 12:30 PM ET

Poster: Recent Advances in ASD Formulations: HIPROS and Dispersome

Presenting Author: Inês Ramos, PhD - Formulation Scientist, Hovione

 

 

 

Let’s discuss your project together.

Schedule a meeting with our experts.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026